BCL2 and breast cancer: Hu et al. tested sabutoclax, a BCL-2 protein family antagonist, in two chemoresistant BC cell lines in vitro and in vivo, showing a significant cytotoxic effect and elimination of the cancer stem cell-like subpopulation.